ASND
Ascendis Pharma A/S
$218.06
+1.14%
$13.5B
No data for this timeframe.
Vol
Market Cap$13.5B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (96%)
Inst. Holders50 funds
Inst. Value$9.1B
Inst. Activity13 buys / 18 sells
Insider Activity4B / 1S
Insider Net $-$4.5M
SEC Reports12
Press Releases4
Recent Activity
Jun 13, 2026
Press
Ascendis Pharma announced sustained efficacy and safety data from the Phase 3 PaTHway Trial of TransCon PTH (YORVIPATH)
Impact 7/10
Jun 13, 2026
fda
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
<p>COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today
Jun 5, 2026
Event
Ibuprofen
Cardiovascular Thrombotic Events Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased r
Jun 2, 2026
Insider
SMITH SCOTT THOMAS bought 100 shares
EVP & Chief Financial Officer @ $219.00 ($21.9K)
May 29, 2026
Insider
SMITH SCOTT THOMAS bought 250 shares
EVP & Chief Financial Officer @ $223.32 ($55.8K)
May 29, 2026
Insider
BIENAIME JEAN JACQUES bought 200 shares
Director @ $223.76 ($44.8K)
May 19, 2026
SEC
Citigroup initiates ASND to Buy — PT $355 (+44.7%)
ANALYST-UPGRADE — Impact 3/10
May 16, 2026
SEC
Morgan Stanley upgrades ASND to Overweight — PT $250 (+1.8% from current, +38.9% from prior)
ANALYST-UPGRADE — Impact 3/10
Price Targets
$298.27
+36.8% upside
Strong Buy
Current $218.06
Low $252.58
Median $295.48
High $354.22
17 analysts
$252.58
$354.22
Analyst Ratings
12Strong Buy
13Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 19, 2026 | Citigroup | INITIATE | Buy |
| May 15, 2026 | Evercore ISI Group | MAINTAIN | Outperform → Outperform |
| May 11, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| May 8, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Apr 16, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.70 ▲ +34.3% | $0.44 — $1.06 | 6 | |
| Next Q | $1.15 ▲ +15.7% | $0.50 — $1.63 | 6 | |
| Current FY | $11.44 ▲ +305.8% | $2.13 — $16.69 | 8 | |
| Next FY | $9.42 ▲ +23.3% | $7.56 — $11.70 | -18% YoY | 8 |
Latest Reports
BULLISH
Press
7/10
Ascendis Pharma announced sustained efficacy and safety data from the Phase 3 PaTHway Trial of TransCon PTH (YORVIPATH)
Jun 13, 2026
BULLISH
ANALYST-UPGRADE
3/10
Citigroup initiates ASND to Buy — PT $355 (+44.7%)
May 19, 2026
BULLISH
ANALYST-UPGRADE
9/10
Morgan Stanley upgraded ASND from Equal-Weight to Overweight with a $250 price target, up from $180, implying 13.4% upsi
Apr 16, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $2.4B | — |
| Avoro Capital Advisors LLC | $1.2B | — |
| FMR LLC | $886.7M | — |
| Artisan Partners Limited Partnership | $738.8M | — |
| FRANKLIN RESOURCES INC | $469.3M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | SMITH SCOTT | BUY | $21.9K |
| May 29, 2026 | SMITH SCOTT | BUY | $55.8K |
| May 29, 2026 | BIENAIME JEAN | BUY | $44.8K |
| May 26, 2026 | BIENAIME JEAN | BUY | $47.2K |
| May 11, 2026 | JENSEN FLEMMING | SELL | $4.6M |
50 institutional holders with $9.1B total value (39,722,428 shares) as of 2026-Q1. Top holders: RA, Avoro, FMR. Net selling activity: 18 institutions trimmed/exited vs 13 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 10,281,496 | $2.4B | 25.9% | — |
| 2 | Avoro Capital Advisors LLC | 5,062,500 | $1.2B | 12.8% | — |
| 3 | FMR LLC | 3,876,601 | $886.7M | 9.8% | — |
| 4 | Artisan Partners Limited Partnership | 3,230,188 | $738.8M | 8.1% | — |
| 5 | FRANKLIN RESOURCES INC | 2,051,948 | $469.3M | 5.2% | — |
| 6 | Capital International Investors | 1,958,843 | $448.0M | 4.9% | TRIM -36.1% |
| 7 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1,860,669 | $425.6M | 4.7% | — |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | 1,757,633 | $402.0M | 4.4% | — |
| 9 | Capital World Investors | 900,517 | $206.0M | 2.3% | NEW |
| 10 | BlackRock, Inc. | 661,054 | $151.2M | 1.7% | ADD +39.1% |
| 11 | Polar Capital Holdings Plc | 651,712 | $149.1M | 1.6% | ADD +75.9% |
| 12 | MORGAN STANLEY | 606,348 | $138.7M | 1.5% | ADD +51.9% |
| 13 | GOLDMAN SACHS GROUP INC | 566,192 | $129.5M | 1.4% | — |
| 14 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 556,427 | $127.3M | 1.4% | — |
| 15 | AMERIPRISE FINANCIAL INC | 476,466 | $109.0M | 1.2% | — |
| 16 | FIL Ltd | 447,421 | $102.3M | 1.1% | — |
| 17 | AMERIPRISE FINANCIAL INC | 411,500 | $94.1M | 1.0% | — |
| 18 | Invesco Ltd. | 362,109 | $82.8M | 0.9% | TRIM -38.2% |
| 19 | SEI INVESTMENTS CO | 351,146 | $80.3M | 0.9% | ADD +37.1% |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 305,500 | $69.9M | 0.8% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Capital International Investors | TRIM | 3,063,943 | 1,958,843 | -36.1% | $448.0M | 2026-Q1 |
| Capital World Investors | NEW | — | 900,517 | — | $206.0M | 2026-Q1 |
| Polar Capital Holdings Plc | ADD | 370,473 | 651,712 | +75.9% | $149.1M | 2026-Q1 |
| Invesco Ltd. | TRIM | 586,094 | 362,109 | -38.2% | $82.8M | 2026-Q1 |
| Pictet Asset Management Holding SA | DOUBLED | 73,418 | 251,833 | +243.0% | $56.9M | 2026-Q1 |
| DEUTSCHE BANK AG\ | TRIM | 296,818 | 135,187 | -54.5% | $30.9M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 117,332 | — | $26.8M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | TRIM | 216,173 | 114,275 | -47.1% | $26.1M | 2026-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | NEW | — | 91,470 | — | $20.9M | 2026-Q1 |
| STATE STREET CORP | ADD | 67,949 | 87,334 | +28.5% | $20.0M | 2026-Q1 |
| LOOMIS SAYLES & CO L P | TRIM | 112,240 | 80,405 | -28.4% | $18.4M | 2026-Q1 |
| NATIONAL BANK OF CANADA /FI/ | NEW | — | 80,017 | — | $18.3M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | DOUBLED | 12,230 | 31,135 | +154.6% | $7.1M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | TRIM | 43,190 | 30,770 | -28.8% | $7.0M | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | TRIM | 71,516 | 30,663 | -57.1% | $7.0M | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 48,260 | 26,200 | -45.7% | $6.0M | 2026-Q1 |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | TRIM | 48,097 | 23,997 | -50.1% | $5.5M | 2026-Q1 |
| Jain Global LLC | NEAR_EXIT | 216,526 | 17,207 | -92.1% | $3.9M | 2026-Q1 |
| Erste Asset Management GmbH | TRIM | 20,300 | 11,200 | -44.8% | $2.4M | 2026-Q1 |
| Nuveen, LLC | TRIM | 9,098 | 6,051 | -33.5% | $1.4M | 2026-Q1 |
| DnB Asset Management AS | TRIM | 5,977 | 3,514 | -41.2% | $803.8K | 2026-Q1 |
| Vident Advisory, LLC | ADD | 1,926 | 2,498 | +29.7% | $571.4K | 2026-Q1 |
| Daiwa Securities Group Inc. | TRIM | 3,104 | 2,269 | -26.9% | $519.0K | 2026-Q1 |
| POLEN CAPITAL MANAGEMENT LLC | ADD | 1,211 | 1,812 | +49.6% | $414.5K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 11 | 118 | +972.7% | $27.0K | 2026-Q1 |
3 unique insiders with 5 transactions. Net insider value: -$4.5M ($169.7K bought, $4.6M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | SMITH SCOTT THOMAS | EVP & Chief Financial Officer | BUY | 100 | $219.00 | $21.9K |
| May 29, 2026 | SMITH SCOTT THOMAS | EVP & Chief Financial Officer | BUY | 250 | $223.32 | $55.8K |
| May 29, 2026 | BIENAIME JEAN JACQUES | Director | BUY | 200 | $223.76 | $44.8K |
| May 26, 2026 | BIENAIME JEAN JACQUES | Director | BUY | 200 | $236.24 | $47.2K |
| May 11, 2026 | JENSEN FLEMMING STEEN | See Remarks | SELL | 19,460 | $238.49 | $4.6M |
12 SEC filing reports analyzed. Sentiment: 9 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 5.6/10.
BULLISH
ANALYST-UPGRADE
3/10
Citigroup initiates ASND to Buy — PT $355 (+44.7%)
May 19, 2026
BULLISH
ANALYST-UPGRADE
9/10
Morgan Stanley upgraded ASND from Equal-Weight to Overweight with a $250 price target, up from $180,
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
3/10
Morgan Stanley upgrades ASND to Overweight — PT $250 (+1.8% from current, +38.9% from prior)
May 16, 2026
BULLISH
6-K
7/10
Ascendis Pharma announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial for TransCon PT
Jun 12, 2026
BULLISH
CLUSTER
4/10
CFO Scott Thomas and Director Jean-Jacques Bienaimé made open-market purchases totaling $67K over a
Jun 2, 2026
BULLISH
6-K
8/10
Ascendis Pharma reported Q1 2026 revenue of €247M (up 144% YoY from €101M), driven by YORVIPATH sale
May 7, 2026
BULLISH
6-K
7/10
Ascendis Pharma reported Q1 2026 revenue of €246.6M (+144% YoY), driven by YORVIPATH sales tripling
May 7, 2026
NEUTRAL
6-K
3/10
Ascendis Pharma A/S updated the International Securities Identification Number (ISIN) for its ordina
Apr 21, 2026
NEUTRAL
6-K
5/10
Ascendis Pharma A/S announced a transition to a direct listing of its ordinary shares on Nasdaq, rep
Apr 8, 2026
BULLISH
6-K
8/10
Ascendis Pharma released new Week 52 data from its Phase 2 COACH trial showing that TransCon CNP and
Apr 8, 2026
BULLISH
6-K
8/10
Ascendis Pharma announced that YUVIWEL (navepegritide), its once-weekly treatment for children with
Apr 7, 2026
NEUTRAL
3
2/10
Jean-Jacques Bienaime, a director or significant insider of Ascendis Pharma, filed a Form 3 to repor
Apr 1, 2026
BULLISH
7/10
Ascendis Pharma announced sustained efficacy and safety data from the Phase 3 PaTHway Trial of Trans
Jun 13, 2026
NEUTRAL
5/10
Ascendis Pharma reported positive subgroup data from the ApproaCH trial of TransCon CNP (navepegriti
May 6, 2026
BULLISH
8/10
Ascendis Pharma announced Week 52 data from its Phase 2 COACH trial showing that the combination of
Apr 8, 2026
BULLISH
7/10
Ascendis Pharma announced positive Week 52 results from its Phase 2 New InsiGHTS trial, showing that
Mar 17, 2026
Current analyst consensus: Strong Buy (96% buy). Based on 26 analysts: 12 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$298.27 mean target
+36.8% upside
Strong Buy (1.24)
$252.58 Low
$354.22 High
| Metric | Value |
|---|---|
| Current Price | $218.06 |
| Target Low | $252.58 |
| Target Mean | $298.27 |
| Target Median | $295.48 |
| Target High | $354.22 |
| # Analysts | 17 |
| Recommendation | Strong Buy (1.24) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.70 | $0.44 | $1.06 | — | +34.3% | — | $0.3B | 110.0% | 6 |
| Next Q 2026-09-30 |
$1.15 | $0.50 | $1.63 | — | +15.7% | — | $0.4B | 65.7% | 6 |
| Current FY 2026-12-31 |
$11.44 | $2.13 | $16.69 | — | +305.8% | — | $1.3B | 85.8% | 8 |
| Next FY 2027-12-31 |
$9.42 | $7.56 | $11.70 | -17.6% | +23.3% | — | $1.9B | 45.2% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.702 | |
| 7d ago | $0.702 | |
| 30d ago | $0.522 | +0.179 |
| 60d ago | $0.000 | +0.702 |
| 90d ago | $0.000 | +0.702 |
9 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 19, 2026 | Citigroup | INITIATE | — | Buy |
| May 15, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| May 11, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 8, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Apr 16, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Apr 9, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Mar 3, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 12, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Feb 12, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Jan 30, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Jan 28, 2026 | Barclays | INITIATE | — | Overweight |
| Jan 20, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 20, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 9, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 7, 2026 | TD Cowen | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 12 | 13 | 1 | 0 | 0 | 96% | |
| May 1, 2026 | 11 | 12 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 11 | 12 | 1 | 0 | 0 | 96% | |
| Mar 1, 2026 | 11 | 12 | 1 | 0 | 0 | 96% | |
| Feb 1, 2026 | 11 | 12 | 1 | 0 | 0 | 96% | |
| Jan 1, 2026 | 11 | 11 | 1 | 0 | 0 | 96% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 13, 2026
fda
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
<p>COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase
Jun 11, 2026
other
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
<p align="center"><em>– Multi-organ system and quality-of-life benefits sustained through five years of treatment</em></p>
Jun 8, 2026
routine
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
<p align="left">COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from
Jun 5, 2026
FDA
Ibuprofen
Cardiovascular Thrombotic Events Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, i
Jun 1, 2026
FDA
CLOPIDOGREL
WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE The effectiveness of clopidogrel tablets res
Jun 1, 2026
FDA
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue olmesartan medoxomil and hydrochlorothiazide tablet as soon as possible [see Warning
May 29, 2026
FDA
EstroGel
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA and BREAST CANCER Estrogen-Alone Therapy Endometrial Cancer There is an incre
May 27, 2026
FDA
Mycophenolate mofetil
WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES and SERIOUS INFECTIONS Use during pregnancy is associated with increased risks of first trimester pregnanc
May 13, 2026
Clinical Trial
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Phase Phase 2 — TERMINATED
May 13, 2026
short_interest
FTD: ASND — 9,023 shares ($2.1M) failed to deliver
Settlement: 20260513, Price: $237.65, FTD Value: $2,144,315.95, ASCENDIS PHARMA A/S SHS USD (D
May 7, 2026
earnings
Ascendis Pharma Reports First Quarter 2026 Financial Results
<p align="center"><em>- Q1 2026 revenue of €197 million for YORVIPATH</em><sup>®</sup> <em>and €44 million for SKYTROFA</em><sup>®</sup></p>
May 6, 2026
fda
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years
<p align="left">COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from a subgroup an
May 6, 2026
short_interest
FTD: ASND — 16,215 shares ($3.7M) failed to deliver
Settlement: 20260506, Price: $225.28, FTD Value: $3,652,915.2, ASCENDIS PHARMA A/S SHS USD (D
May 5, 2026
short_interest
FTD: ASND — 16,175 shares ($3.7M) failed to deliver
Settlement: 20260505, Price: $228.71, FTD Value: $3,699,384.25, ASCENDIS PHARMA A/S SHS USD (D
May 4, 2026
short_interest
FTD: ASND — 14,338 shares ($3.2M) failed to deliver
Settlement: 20260504, Price: $220.93, FTD Value: $3,167,694.34, ASCENDIS PHARMA A/S SHS USD (D
May 1, 2026
short_interest
FTD: ASND — 3,615 shares ($0.8M) failed to deliver
Settlement: 20260501, Price: $229.38, FTD Value: $829,208.7, ASCENDIS PHARMA A/S SHS USD (D
Apr 30, 2026
short_interest
FTD: ASND — 5,558 shares ($1.2M) failed to deliver
Settlement: 20260430, Price: $220.28, FTD Value: $1,224,316.24, ASCENDIS PHARMA A/S SHS USD (D
Apr 29, 2026
short_volume
Short Volume: ASND — 91.5% short (1.2M / 1.3M)
Short: 1,215,379 | Exempt: 15 | TRF Vol: 1,328,007 | Short Ratio: 91.5% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
earnings_calendar
ASND Q1 2026 Earnings After Market Close — 2026-04-29
Apr 28, 2026
short_interest
FTD: ASND — 34,042 shares ($7.7M) failed to deliver
Settlement: 20260428, Price: $226.66, FTD Value: $7,715,959.72, ASCENDIS PHARMA A/S SHS USD (D
Apr 28, 2026
short_volume
Short Volume: ASND — 69.5% short (1.2M / 1.7M)
Short: 1,187,135 | Exempt: 92,714 | TRF Vol: 1,707,448 | Short Ratio: 69.5% | Off-exchange volume (dark pool + OTC)